GHK-Cu Research: Gene Expression, Wound Repair & Skin Remodelling Data
A study-by-study look at GHK-Cu — the copper tripeptide's gene-expression signature, its wound-repair models and the controlled cosmetic trials that followed.
Mechanism of action
GHK is a naturally occurring tripeptide, glycyl-L-histidyl-L-lysine, first isolated from human plasma by Loren Pickart in 1973. Plasma levels fall sharply with age — from around 200 ng/ml at age 20 to roughly 80 ng/ml by age 60.
GHK has a very high affinity for copper(II) ions. The resulting GHK-Cu complex acts as a copper carrier, delivering the ion to enzymes involved in collagen synthesis, antioxidant defence and tissue remodelling.
The most cited mechanism is transcriptional: broad gene-expression analysis reports that GHK modulates the expression of a large fraction of human genes, resetting expression of wound-repair, antioxidant and DNA-repair programmes toward a younger profile.
Downstream effects reported in tissue models include stimulation of collagen, elastin and glycosaminoglycan synthesis, modulation of matrix metalloproteinases and their inhibitors, and attenuation of inflammatory signalling.
The studies
The GHK-Cu literature spans four decades: biochemistry from the 1970s and 80s, transcriptomic work from the 2010s, and a set of small controlled dermatology trials. The strongest evidence is mechanistic and dermatological.
Broad-scale gene expression analysis of GHK
To characterise which human genes GHK modulates, using the Broad Institute Connectivity Map dataset and follow-up transcriptomic analyses.
Connectivity Map gene-expression profiling · human cell lines · comparison against reference perturbation signatures
- ~4,000
- Human genes with altered expression
- Repair-associated
- Direction of change
- Down-regulated
- Inflammatory / fibrotic genes
reported across analyses
DNA repair, antioxidant, remodelling programmes up
- This analysis is the foundation of the modern GHK-Cu literature and the reason interest broadened from cosmetics to tissue repair generally.
- The signature is consistent with the older wound-healing observations rather than contradicting them.
- It remains a transcriptomic result in cell systems — gene expression shifts are not the same as clinical outcomes.
Wound healing and tissue repair models
To assess whether topical or injected GHK-Cu accelerates closure and improves quality of repair in experimental wound models.
Rodent, rabbit and porcine wound models · surgical, ischaemic and diabetic wound designs
- Accelerated
- Wound closure rate
- Increased
- Collagen deposition
- Increased
- Angiogenesis markers
vs vehicle controls
VEGF and related signalling
- Wound-model work is the most reproduced part of the GHK-Cu evidence base, replicated across species and wound types.
- Effects were most pronounced in impaired-healing models — ischaemic and diabetic wounds — rather than healthy tissue.
- Animal wound models translate imperfectly to human clinical practice; treat as supportive, not confirmatory.
Controlled facial-skin trials of copper-peptide creams
To evaluate whether copper-tripeptide topical formulations improve photoaged facial skin against placebo and active comparators such as vitamin C and retinoic acid.
Small randomised, controlled dermatology trials · 12 weeks · instrumental and blinded-assessor measures
- Increased
- Skin density and thickness
- Improved
- Fine-line appearance
- Small
- Trial sizes
vs placebo
typically tens of participants
- These trials are why copper peptides became a mainstream cosmetic ingredient rather than a laboratory curiosity.
- Reported improvements were comparable to or better than vitamin C in the same designs, with less irritation than retinoic acid.
- Participant numbers were small and many trials were industry-sponsored — read the primary reports before quoting effect sizes.
Storage & handling
GHK-Cu research material is supplied as a lyophilised powder with the characteristic blue colour of the copper complex. Store sealed vials refrigerated or frozen, protected from light.
Reconstitute with bacteriostatic water added slowly down the inner wall; swirl gently until dissolved. The solution should be a clear blue — cloudiness or a colour shift indicates degradation.
Keep reconstituted solution at 2-8 °C, away from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.